Carisma Therapeutics Earnings Date & Estimates

Carisma Therapeutics (NASDAQ:CARM), Inc. is a clinical-stage biotechnology company focused on developing therapies that harness and genetically engineer myeloid cells, including monocytes and macrophages, to treat cancer and other serious diseases. The company’s platform is designed to create engineered immune cells that can recognize disease-associated targets, enter solid tumors and alter the tumor microenvironment.

Carisma’s primary product candidate is CT-0525, an investigational HER2-targeted chimeric antigen receptor (CAR) monocyte therapy being developed for patients with advanced solid tumors. Unlike conventional CAR-T therapies, Carisma’s approach is intended to use monocytes that can circulate through the bloodstream, migrate into tumors and differentiate into macrophages. The company is also advancing additional preclinical and clinical programs based on its engineered myeloid-cell platform.

Carisma Therapeutics was founded in 2016 and is headquartered in Philadelphia, Pennsylvania. The company’s technology originated from research conducted at the University of Pennsylvania and was developed through a collaboration involving Penn and its scientific founders. Carisma’s programs are being developed for potential use in oncology, with clinical development and research activities focused primarily in the United States. Steven Kelly serves as the company’s president and chief executive officer.